Rayner Surgical patents expiration
1. Omidria patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8586633 | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jul, 2023
(a month ago) | |
| US9278101 | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jul, 2023
(a month ago) | |
| US8173707 | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jul, 2023
(a month ago) | |
| US9399040 | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jul, 2023
(a month ago) | |
|
US9399040 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(4 months from now) | |
|
US8173707 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(4 months from now) | |
|
US8586633 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(4 months from now) | |
|
US9278101 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(4 months from now) | |
| US9486406 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(10 years from now) | |
| US9066856 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(10 years from now) | |
| US9855246 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(10 years from now) | |
|
US9486406 (Pediatric) | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Apr, 2034
(10 years from now) | |
|
US9066856 (Pediatric) | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Apr, 2034
(10 years from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2014
Treatment: Maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain
Dosage: SOLUTION;IRRIGATION
How can I launch a generic of OMIDRIA before it's drug patent expiration?
More Information on Dosage
OMIDRIA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic